(EN) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
WO44263
NCT05894239
 Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
 HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
|
Marie-Anne Capobianco
514-338-2222 poste 3493
|
(EN) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
EMBER-4
NCT05514054
Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
|
Marie-Anne Capobianco
514-338-2222 poste 3493
|
(EN) An interventional safety and efficacy phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of arv-471 (pf-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study a (arv-471 in combination with abemaciclib)
TACTIVE-U
NCT05548127
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
Étude de phase 3, ouverte, randomisée, comparant le gédatolisib associé au fulvestrant et avec ou sans palbociclib aux traitements standard chez des patientes atteintes d'un cancer du sein avancé HR-positif, HER2-négatif précédemment traitées avec un inhibiteur CDK4/6 en association avec traitement par inhibiteur non stéroïdien de l'aromatase
VIKTORIA-1
NCT05501886
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Mary-Denise Dufour
418-541-1000 poste 2823
|
(EN) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Mary-Denise Dufour
418-541-1000 poste 2823
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
(EN) Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
ELISA
NCT04797299
Actif en recrutement
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
|
Caroline Hivon
450-466-5000 poste 2164
|
(EN) An interventional safety and efficacy phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of ARV-471 (PF-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study B (ARV-471 in combination with ribociclib)
TACTIVE-U
NCT05573555
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Alexandra Simard
418-541-1000 poste 3163
|
(EN) An interventional, open-label, randomized, multicenter phase 3 study of PF-07220060 plus fulvestrant compared to investigator's choice of therapy in participants over 18 years of age with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer whose disease progressed after prior CDK 4/6 inhibitor-based therapy
C4391022
NCT06105632
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
(EN) A phase 3, randomized, open-label, multicenter trial of ARV-471 (PF-07850327) vs fulvestrant in participants with estrogen receptor-positive, her2-negative advanced breast cancer whose disease progressed after prior endocrine based treatment for advanced disease
VERITAC-2
NCT05654623
Actif en recrutement
|
CISSS DES LAURENTIDES
HOPITAL DE SAINT-JEROME
|
|
Yanick Sardin Laframboise
450-431-1020 poste 23429
|
Groupe d'étude en oncologie du Québec